Jardiance (Empagliflozin)

Empagliflozin blocks the sodium‑glucose co‑transporter 2 (SGLT2) in the kidney’s proximal tubules, reducing glucose reabsorption. The excess glucose is expelled in the urine, which lowers blood sugar levels and provides modest diuretic effects that contribute to cardiovascular benefits.

The dose of Jardiance is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of empagliflozin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Jardiance, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other oral antidiabetics, empagliflozin offers glucose‑lowering efficacy together with proven cardiovascular risk reduction. Unlike some agents, it works independently of insulin secretion, which can be advantageous for patients with beta‑cell dysfunction, but it also carries a distinct safety profile that requires monitoring.

Jardiance should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product away from excessive heat and do not store in a bathroom or other humid environments.

Jardiance is taken orally, usually once daily in the morning, with or without food. The tablet should be swallowed whole with a glass of water and not crushed, chewed, or split unless specifically instructed by a healthcare professional.

The most serious risks include ketoacidosis, severe dehydration, acute kidney injury, and rare but life‑threatening infections such as Fournier’s gangrene. Patients should be educated to recognize early symptoms and seek immediate medical attention if they occur.

Jardiance is contraindicated in patients with severe renal impairment, end‑stage renal disease, or those on dialysis. It should also be avoided in individuals with a known hypersensitivity to empagliflozin or any component of the formulation.